CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,005 enrolled
Drug / intervention
Urokinase thrombolysis +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04420351
NCT04420351Phase 3Completed

A Phase ⅢB, Prospective, Randomized, Open Label, Blinded-endpoint, Multicenter Trial of the Efficacy and Safety of Urokinase Thrombolysis Comparing With Antiplatelet Agents for Patients With Minor Stroke.

The First Affiliated Hospital of Zhengzhou University·interventional·Posted Jun 9, 2020·Updated Nov 14, 2023

In Brief

A Phase 3 clinical trial evaluating Urokinase thrombolysis and Aspirin;Clopidogrel for Minor Stroke. Completed, enrolled 1,005 participants across 1 site.

Detailed Summary

This trial will enroll patients that have been diagnosed with minor stroke, which has occurred within the past 6 hours. TRUST is a prospective multicenter, randomized, blinded-endpoint study to evaluate the efficacy and safety of Urokinase Thrombolysis for patients with minor stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMinor Stroke
CountriesChina

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJun 9, 2020
Enrollment StartOct 4, 2020
Primary CompletionFeb 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.1 years ago

Interventions

Urokinase thrombolysisdrug

The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.

Aspirin;Clopidogreldrug

The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.